US Asthma and COPD Therapeutics Market Analysis

US Asthma and COPD Therapeutics Market Analysis: Executive Summary

The US Asthma and COPD Therapeutics Market is at around US $14.03 Bn in 2022 and is projected to reach US $18.05 Bn in 2030, exhibiting a CAGR of 3.20% during the forecast period.

Asthma and Chronic Obstructive Pulmonary Disease (COPD) are persistent respiratory conditions impacting the airways, resulting in breathing challenges. Asthma involves inflammation and constriction of the airways, often triggered by allergens, irritants, or physical activity. Indicative symptoms encompass wheezing, shortness of breath, chest tightness, and coughing, with risk factors including a family history, and respiratory infections. COPD comprises chronic bronchitis and emphysema, resulting in obstructed airways. Smoking stands out as a primary risk factor for COPD, with common symptoms including a chronic cough, heightened mucus production, and fatigue. Treatment for both asthma and COPD entails the use of bronchodilators to relieve airway constriction and anti-inflammatory medications to address inflammation. Various pharmaceutical companies, such as GlaxoSmithKline, AstraZeneca, and Boehringer Ingelheim, manufacture these medications. Advancements in future therapeutics for Asthma and COPD focus on innovative anti-inflammatory agents, bronchodilators, and targeted therapies tailored to specific aspects of these conditions

Approximately 16 million Americans are estimated to be affected by COPD, and over 25 million adults currently reside with asthma in the United States. These estimates directly correspond to the increased risk factor of smoking within the population. The market is being driven by factors such as the rising prevalence of asthma and COPD, increased healthcare spending, advancements in treatments, and others. However, high treatment costs for long term management, unmet medical needs, and poor patient adherence are a few factors that limit the market's potential.

Market Dynamics

Market Growth Drivers

Increasing prevalence: It is estimated that over 16 million Americans are currently living with COPD, accounting for roughly 6.5% of the population. Subsequently, every 1 in 12 adults in America suffers from asthma, with over 25 million adults and around 7 million children suffering from asthma in the US. This translates to an increased number of patients, which include smokers, children, people living in poverty, and certain ethnic groups in need of treatment, contributing to a growing demand for therapeutics.

Increased healthcare spending: The increased awareness of the economic impact of COPD and asthma prompts a rise in healthcare expenditures for the diagnosis, treatment, and management of these conditions. This trend proves advantageous for companies providing cost-effective and value-based treatment alternatives. The augmented funding also facilitates research for groups such as the American Lung Association, development, and the integration of new therapeutics, driving the expansion of the market.

Environmental conditions: Increasing concerns about the role of air pollution and environmental factors in the rise of COPD and asthma cases drive a push for preventive measures and early intervention in the US. This, in turn, favours the market for diagnostic tools and medications.

Advanced treatments: Continuous progress in drug delivery devices and formulations enhances the effectiveness of medications, promotes adherence, and increases patient convenience in US. This progression propels the market expansion for inhalers, nebulizers, and other delivery systems.

Market Restraints

High treatment costs: The long-term management of COPD and asthma entails the utilization of medications and devices, placing a significant economic burden on both individuals and healthcare systems. The expense associated with newer and more efficacious medications is considerable, and not everyone has adequate insurance coverage to cover these costs. This circumstance may lead to a lack of adherence to medication and contribute to less-than-ideal health outcomes.

Unmet medical needs: Owing to the huge patient population, there is a shortage of effective therapies and human resources for asthma and COPD. This results in delayed diagnosis and treatment seeking for this condition, which restricts market growth.

Poor patient adherence: Effectively managing COPD and asthma frequently necessitates the daily usage of inhalers and other medications, posing challenges for certain patients. Issues such as forgetfulness, challenges in proper inhaler usage, and potential side effects may contribute to suboptimal adherence, ultimately diminishing the effectiveness of the treatment.

Lack of specialists: There is a deficiency of pulmonologists and other specialists with the capability to accurately diagnose and treat COPD and asthma, particularly in rural regions. This limited accessibility may lead to delays in both diagnosis and treatment, contributing to the advancement of these diseases and their potential complications.

Notable Updates

November 2023, Dupixent® (dupilumab) from Sanofi demonstrated a substantial reduction in COPD exacerbations in the second positive Phase 3 trial. This outcome has expedited the submission to the FDA and affirms its potential to become the first approved biologic for this severe disease.

July 2023, Breyna™ (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, developed by Viatris, becomes the first FDA-approved generic version of Symbicort® for individuals dealing with asthma and COPD, in collaboration with Kindeva.

January 2023, AstraZeneca's Airsupra (albuterol/budesonide), previously identified as PT027, received approval in the United States for the on-demand treatment or prevention of bronchoconstriction and to minimize the risk of exacerbations in individuals aged 18 years and older with asthma.

Healthcare Policies and Regulatory Landscape

The healthcare policy and regulatory framework in the United States are intricate and diverse, incorporating a collaboration between federal and state entities. At the national level, the Department of Health and Human Services (HHS) assumes a pivotal role in supervising overarching health policies. Critical agencies under the purview of HHS, such as the Centres for Medicare & Medicaid Services (CMS), the Food and Drug Administration (FDA), and the Centres for Disease Control and Prevention (CDC), are assigned distinct responsibilities related to healthcare oversight, drug approval processes, and public health initiatives.

The procedure for acquiring a healthcare license in the United States varies depending on the profession and is generally under state jurisdiction. State medical boards, or licensing authorities, are tasked with granting licenses to healthcare professionals, including doctors, nurses, and other practitioners. The standard procedure entails the completion of requisite education and training from accredited institutions, the successful passage of relevant licensing examinations, and the fulfillment of any additional state-specific prerequisites.

Competitive Landscape

Key Players

• GlaxoSmithKline
• AstraZeneca
• Boehringer-Ingelheim Pharmaceuticals
• Novartis
• Pfizer
• Teva US Limited
• ResMed
• Hill-Rom
• Abbott Laboratories
• Adamis Pharmaceuticals Corporation